Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Rheumatic Heart Disease III: Medical Management

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Spectrally Resolved (Colour-Coded) Fundus Autofluorescence Using the EIDON System in Vitreoretinal Lymphoma.

Ophthalmology and therapy·2026

Same author

Beyond placoid: diverse clinical presentations and functional outcomes of acute syphilitic posterior placoid chorioretinopathy.

Eye (London, England)·2026

Same author

Salvage Irradiation for Ocular Adnexal Mucosa Associated Lymphoid Tissue Lymphoma Refractory to <i>Chlamydia psittaci</i> Eradication.

Advances in radiation oncology·2025

Same author

The Silent Masquerade: Clinical and Imaging Features of Asymptomatic Vitreoretinal Lymphoma.

American journal of ophthalmology·2024

Same author

Unraveling the Spectrum of Uveitis: Insights from an Epidemiological Study in a National Referral Center in Northern Italy.

Ocular immunology and inflammation·2024

Same author

Ocular complications of SAVI: A unique case of bilateral uveitis and retinal vasculitis.

American journal of ophthalmology case reports·2024

Search research articles

Related Experiment Video

Updated: May 23, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Rituximab for noninfectious uveitis.

Elisabett Miserocchi¹, Giulio Modorati

¹Ocular Immunology and Uveitis Service, Department of Ophthalmology and Visual Sciences, San Raffaele Scientific Institute, University Vita-Salute, Milan, Italy.

Developments in Ophthalmology

|April 21, 2012

Summary

This summary is machine-generated.

Rituximab (RTX), a CD20-targeting antibody, shows promise for severe ocular inflammatory diseases. While generally well-tolerated, further research is needed to confirm its efficacy and optimal dosing for these challenging conditions.

More Related Videos

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Related Experiment Videos

Last Updated: May 23, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Primed Mycobacterial Uveitis (PMU) as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Area of Science:

Ophthalmology
Immunology
Rheumatology

Background:

Rituximab (RTX) is a monoclonal antibody targeting CD20+ B cells.
It is established in treating lymphomas and systemic autoimmune diseases.
Growing evidence suggests RTX efficacy in ocular inflammatory conditions.

Purpose of the Study:

To review the utility of RTX in managing ocular inflammatory diseases.
To highlight its potential in refractory and sight-threatening ocular conditions.

Main Methods:

Literature review of case reports and studies on RTX for ocular inflammation.
Analysis of RTX's safety and tolerability profile.

Main Results:

RTX has been used for refractory scleritis, peripheral ulcerative keratitis, uveitis, ocular cicatricial pemphigoid, and conjunctival lymphoma.
The drug demonstrates good tolerability, with infusion reactions being the most common adverse events.
RTX appears effective in aggressive, recalcitrant, and sight-threatening ocular inflammation and uveitis.

Conclusions:

Rituximab may be a valuable treatment option for severe ocular inflammatory diseases.
It is particularly considered for cases unresponsive to conventional therapies or other biologics.
Further studies are warranted to establish optimal dosing and confirm efficacy.